Cold Urticaria: Release into the Circulation of Histamine and Eosinophil Chemotactic Factor of Anaphylaxis during Cold Challenge

New England Journal of Medicine

Volumn 294, Issue 13, 1976, Pages 687-690

  Soter, Nicholas A ^a   Wasserman, Stephen I ^a   Austen, K Frank ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; HISTAMINE;

ANAPHYLAXIS; CHEMOTAXIS; COLD URTICARIA; EOSINOPHIL; ETIOLOGY; MAJOR CLINICAL STUDY; NORMAL HUMAN; THEORETICAL STUDY;

EID: 0017289274     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM197603252941302     Document Type: Article

References (30)

1. Sherman W.B., Seebohm P.M.: Passive transfer of cold urticaria. J Allergy 21: 414–424, 1950
2. Houser D.D., Arbesman C.E., Ito K, et al: Cold urticaria: immunologic studies. Am J Med 49: 23–33, 1970
3. Rose B: Histamine, hormones, and hypersensitivity. J Allergy 25: 168–189, 1954
4. Henderson L.L., Code C.F., Roth G.M.: Increased blood histamine in thermal intolerance: report of a patient with cryoglobulinemia. J Allergy 29: 122–129, 1958
5. Beall G.N.: Plasma histamine concentrations in allergic diseases. J Allergy 34: 8–15, 1963
6. Kaplan A.P., Gray L, Shaff R.E., et al: In vivo studies of mediator release in cold urticaria and cholinergic urticaria. J Allergy Clin Immunol 55: 394–402, 1975
7. DeLaus F.V., Winkelmann R.K.: Kinins in cold urticaria. Arch Dermatol 98: 67–74, 1968
8. Beaven M.A., Jacobsen S, Horáková Z: Modification of the enzymatic isotopic assay of histamine and its application to measurement of histamine in tissues, serum and urine. Clin Chim Acta 37: 91–103, 1972
9. Wasserman S.I., Goetzl E.J., Austen K.F.: Preformed eosinophil chemotactic factor of anaphylaxis (ECF-A). J Immunol 112: 351–358, 1974
10. Boyden S: The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes. J Exp Med 115: 453–466, 1962
11. Goetzl E.J., Gigli I, Wasserman S, et al: A neutrophil immobilizing factor derived from human leukocytes. I.I Specificity of action on polymorphonuclear leukocyte mobility. J Immunol 111: 938–945, 1973
12. Kay A.B., Stechschulte D.J., Austen K.F.: An eosinophil leukocyte chemotactic factor of anaphylaxis. J Exp Med 133: 602–619, 1971
13. Goetzl E.J., Austen K.F.: A neutrophil-immobilizing factor derived from human leukocytes. I. Generation and partial characterization. J Exp Med 136: 1564–1580, 1972
14. Kent J.F., Fife E.H. Jr: Precise standardization of reagents for complement fixation. Am J Trop Med Hyg 12: 103–116, 1963
15. Ruddy S, Klemperer M.R., Rosen F.S., et al: Hereditary deficiency of the second component of complement (C2) in man: correlation of C2 haemolytic activity with immunochemical measurements of C2 protein. Immunology 18: 943–954, 1970
16. Ruddy S, Austen K.F.: C3 inactivator of man. I. Hemolytic measurement by the inactivation of cell-bound C3. J Immunol 102: 533–543, 1969
17. Lewis E.J., Carpenter C.B., Schur P.H.: Serum complement component levels in human glomerulonephritis. Ann Intern Med 75: 555–560, 1971
18. Kohler P.F., Müller-Eberhard H.J.: Immunochemical quantitation of the third, fourth and fifth components of human complement: concentrations in the serum of healthy adults. J Immunol 99: 1211–1216, 1967
19. Hunsicker L.G., Ruddy S, Carpenter C.B., et al: Metabolism of the third complement component (C3) in nephritis: involvement of the classic and alternate (properdin) pathways for complement activation. N Engl J Med 287: 835–840, 1972
20. Fearon D.T., Austen K.F., Ruddy S: Properdin factor D. I.I. Activation to D̄ by properdin. J Exp Med 140: 426–436, 1974
21. Mancini G, Carbonara A.O., Heremans J.F.: Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 2: 235–254, 1965
22. Soter N.A., Austen K.F., Gigli I: The complement system in necrotizing angiitis of the skin: analysis of complement component activities in serum of patients with concomitant collagen-vascular diseases. J Invest Dermatol 63: 219–226, 1974
23. Spitz E, Gelfand E.W., Sheffer A.L., et al: Serum IgE in clinical immunology and allergy. J Allergy Clin Immunol 49: 337–347, 1972
24. Goetzl E.J., Austen K.F.: Purification and synthesis of eosinophilotactic tetrapeptides of human lung tissue: identification as eosinophil chemotactic factor of anaphylaxis (ECF-A). Proc Natl Acad Sci U.S.A 72: 4123–4127, 1975
25. Weiss S, Robb G.P., Ellis L.B.: The systemic effects of histamine in man: with special reference to the responses of the cardiovascular system. Arch Intern Med 49: 360–396, 1932
26. Lecomte J: Liberation of endogenous histamine in man. J Allergy 28: 102–112, 1957
27. Vallota E.H., Müller-Eberhard H.J.: Formation of C3a and C5a anaphylatoxins in whole human serum after inhibition of the anaphylatoxin inactivator. J Exp Med 137: 1109–1123, 1973
28. Nilsson U.R., Mandle R.J. Jr., McConnell-Mapes J.A.: Human C3 and C5: subunit structure and modifications by trypsin and C4̄2̄-C4̄2̄3̄. J Immunol 114: 815–822, 1975
29. Lewis R.A., Goetzl E.J., Wasserman S.I., et al: The release of four mediators of immediate hypersensitivity from human leukemic basophits. J Immunol 114: 87–92, 1975
30. Kaliner M, Wasserman S.I., Austen K.F.: Immunologic release of chemical mediators from human nasal polyps. N Engl J Med 289: 277–281, 1973